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The purpose of this open retrospective study was to analyze the efficacy and tolerability of vagal nerve stimulation (VNS) in a
Norwegian cohort of referral patients with refractory epileptic seizures. A total of 47 patients have been assessed after a mean
follow-up time of 2.7 years. Mean age was 34.4 years, mean duration of epilepsy was 25.3 years. Forty-two patients (89%) had
localization-related epilepsy, 36 patients (77%) had daily seizures. The patients had tried on average 9.5 antiepileptic drugs, and
12 patients (26%) had undergone epilepsy surgery.
Sixteen patients (34%) had >50% reduction of seizure frequency with VNS, of which one patient became seizure free. The
stimulation was generally well tolerated, but three patients requested the device removed because of troublesome side effects.
We conclude that VNS is an efficacious and safe mode of treatment that should be offered to patients with medically and
surgically refractory seizures.
© 2002 BEA Trading Ltd. Published by Elsevier Science Ltd. All rights reserved.
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INTRODUCTION
During the last 10 years vagal nerve stimulation (VNS)
has been utilized to an increasing extent as adjunctive
therapy to patients with difficult-to-treat partial on-
set seizures. Despite an increasing amount of clinical
data, it is still not possible to predict which patients
will profit from VNS, and, moreover, the exact mech-
anisms by which VNS exerts its antiepileptic effect
still remain unknown.
The purpose of this open, uncontrolled, retrospective
study was to analyze efficacy and tolerability of VNS
in a Norwegian epilepsy population. By characterizing
the responders, would it be possible to find subgroups
of patients most likely to respond to VNS? Do the
results justify the costs and efforts associated with
the treatment? Should VNS be an integral part of our
future therapeutic armamentarium? And if so, how
soon should patients be offered this treatment?
PATIENTS
From June 1993 to December 1999, a total of 47 pa-
tients have had a vagus nerve stimulator implanted at
the National Hospital in Oslo. The clinical features of
the patients are shown in Table 1. All the patients were
recruited from those referred to the National Centre
for Epilepsy in Sandvika. Most of these patients
have refractory epilepsy, and those selected for VNS
were considered particularly difficult-to-treat. This is
illustrated by the fact that the patients still had weekly
seizures, 3/4 had even daily seizures, despite having
tried on average 9.5 antiepileptic drugs (AEDs) and
that 1/4 had undergone epilepsy surgery. The patients
had a mean seizure history of 25 years. The vast ma-
jority of the patients (89%) had a localization-related
epilepsy with simple and/or complex partial seizures
with or without secondary generalization. Eight of the
patients were mentally retarded, three of whom had
Lennox–Gastaut syndrome. Only five patients (11%)
were fully employed, 36 patients (77%) received
disablement benefit.
METHOD
Stimulation of the left vagal nerve was performed uti-
lizing the Neurocybernetic Prosthesis (NCP)-system
(Cyberonics Inc., Houston, TX). This system and the
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Table 1: Patients with vagus nerve stimulatora.
Male/female 20/27
Mean age (range) 34.4 years (12–70 years)
Mean duration of epilepsy (range) 25.3 years (6–68 years)
Etiology
Unknown 26 patients (55%)
Known 21 patients (45%)
CNS infection 7 patients
Cortical dysplasia 4 patients
Cerebrovascular insult 3 patients
CNS trauma 3 patients
Birth-related cerebral asphyxia 3 patients
AVM 1 patient
Epilepsy syndrome
Localization-related 42 patients
Symptomatic 18 patients
Cryptogenic 24 patients
Generalized 5 patients
Symptomatic 3 patients (LGS: 2)
Cryptogenic 1 patient (LGS)
Idiopatic 1 patient (JME)
Seizure frequency in the baseline period
>1 seizure per week 47 patients (100%)
>1 seizure per day 36 patients (77%)
Suffered SE 17 patients (36%)
Mean number of AEDs tried 9.53 (6–13)
Mean number of AEDs in use during baseline period 2.45 (1–5)
Undergone epilepsy surgery 12 patients (26%) (13 operations)
9 temporal lobectomy
2 extratemporal resections
1 MST
1 hemispherectomy
Mental retardation 8 patients (17%)
Permanent neurological sequela 12 patients (26%)
CNS: central nervous system; AVM: arteriovenous malformation; LGS: Lennox–Gastaut syndrome; JME: juvenile myoclonic epilepsy;
SE: status epilepticus; AEDs: antiepileptic drugs; MST: multiple subpial transection.
a Clinical data (n = 47).
surgical procedure have previously been described1–4
. Stimulation was initiated 1–2 weeks postoperatively,
using parameters of current 0.5–1.25 mA, frequency
30 Hz, pulse width 500 microseconds, and on/off pe-
riods of 30 seconds/300 seconds. On subsequent visits
the current was gradually increased to tolerance.
The patients were monitored at regular intervals,
usually every 2–4 weeks during the ramping-up pe-
riod. Later on they were monitored every 3–6 months.
The magnet activation permitted stimulation on de-
mand. The magnet output current was programmed at
0.25–0.5 mA, higher than the automatically delivered
stimulation with a pulse width of 500 microseconds
for a period of 60 seconds. Patients who had no
seizure-reducing effect 1–1.5 years after implantation
were offered a rapid cycling regimen, which consisted
of on/off periods of 7 seconds/14 seconds.
All patients or their relatives were requested to keep
seizure calenders. At every visit seizure frequency,
seizure semiology, seizure duration, postictal state,
prescribed AEDs, and dosages as well as side effects
of VNS were recorded. The VNS effect was assessed
by comparing the seizures in a 3-month baseline pe-
riod prior to the implantation to the most recent seizure
parameters. After 1–1.5 year post implantation, no
restrictions were placed on changes of the concomi-
tant AEDs. The mean follow-up time was 2.7 years
(0.4–6.5 years).
On two occasions (April 1997 and January 2000)
the patients or their relatives were asked to fill in a
questionnaire aiming at getting the patients’ perspec-
tive on the changes in seizure parameters, side effects,
quality of life, and if they had benefited from use of
the magnet.
RESULTS
The surgical procedure was uncomplicated, and the
postoperative period was uneventful for all patients
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Table 2: Effect of vagus nerve stimulation on seizure frequency and self-reported quality of life (n = 47).
Number of patients (%) Number of patients reporting a better
quality of life post implantation (%)
Seizure free 1 (2) 1 (2)
>50% seizure reduction 15 (32) 11 (23)
<50% seizure reduction 11 (23) 4 (9)
No effect 20 (43) 2 (4)
Seizure aggravation 0 (0) 0 (0)
except for one who was explanted after 4 months due
to a local infection at the implant.
The effect of VNS on seizure frequency is shown
in Table 2. One patient became seizure free; a
31-year-old man, fully employed, with epilepsy
onset at 14 years of age. He had a cryptogenic
localization-related epilepsy with daily simple and
complex partial seizures with occasionally secondary
generalization in the pre-VNS period. After implanta-
tion his seizure frequency gradually decreased, but he
was not seizure free until 1.5 years after the implan-
tation. Furthermore, 15 patients had >50% reduction
in seizure frequency, defined as responders. Thus, a
total of 16 patients (34%) were responders. All the
responders had localization-related epilepsies with
an even distribution between symptomatic and cryp-
togenic forms. The responders did not differ from
the non-responders with regard to etiology, localiza-
tion of seizure onset, or ictal semiology. None of
the patients with generalized epilepsy were respon-
ders. Among the three patients with Lennox–Gastaut
syndrome, one had <50% reduction in seizure fre-
quency, the other two had no change in seizure
frequency.
The time interval between the implantation and on-
set of the seizure-reducing effect varied considerably
among the responders. In some patients the effect was
apparent after a few weeks, while in others the ef-
fect gradually emerged and increased over months and
even years. Three of the patients had an initial effect
that gradually disappeared after 3–9 months. Eight pa-
tients were switched to a rapid cycling regimen. Three
patients gained by the switch, but did not reach >50%
seizure reduction. The remaining five had no effect of
rapid cycling regimen.
The side effects are shown in Table 3. Most of these
were associated with the stimulation. They were easily
tolerated, and the majority of the patients tended to ha-
bituate to the symptoms. Fourteen patients (30%) had
their device removed after a mean of 2.2 years (0.3–4.3
years). The reasons for the explantation, as shown in
Table 4, were mainly lack of efficacy. Three patients
wanted to have the device removed, partly due to a
moderate or no seizure-reducing effect and partly due
to disabling side effects. Three patients were explanted
due to device complications, i.e., a lead fracture.
Table 3: Vagus nerve stimulationa.
Number of
patients (%)
Of the 47 patients 36 reported side effects
Hoarseness during stimulation 30 (64)
Unpleasant feeling in the throat
or left jaw during stimulation
11 (23)
Coughing, hawking, parestesia in
the throat during stimulation
9 (19)
Feeling of being strangled
during stimulation
5 (11)
Shortness of breath during
stimulation
2 (4)
Sleep disturbances, snorelike
sounds during sleep
2 (4)
Episodic stomach ache 1 (2)
Local chest pain 1 (2)
Menstrual disturbances 1 (2)
Oesophagitis 1 (2)
a Self-reported side-effects (n = 36).
Three patients died. One died from a heart disease,
one was found drowned, and one suffered a probable
SUDEP.
Sixteen patients (34%) reported that they had achie-
ved a better quality of life as a consequence of VNS.
Most of these were responders (11 patients). Unex-
pectedly, five patients claimed to have achieved a
better life despite only moderate (three patients), or
no (two patients) reduction in seizure frequency. Both
their ictal and postictal symptoms were of shorter du-
ration, they felt more alert, better concentrated, and
were in a better mood. Some of the responders re-
ported a decreased need of diazepam to stop ongoing
seizures, fewer hospitalizations, and days off work.
Eighteen patients (38%) would have chosen VNS
again. However, three of the responders assessed the
reduction in seizure frequency too little to justify
Table 4: Reasons for explantation of the device (n =14).
Number of
patients
Of the 47 patients 4 have been explanted
Lack of efficacy 10
Embarrassing side effects 3
Lead fracture 3
Infection surrounding the device 1
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another implantation. Twenty-two patients (47%)
reported to have benefited from use of the magnet.
DISCUSSION
Both the efficacy and side effects achieved by VNS
in this study in a very difficult-to-treat epilepsy
population are comparable to the results from both
short-term and long-term follow-up studies previ-
ously reported4–10. There is a current agreement that
1/3 of patients experience a seizure reduction of at
least 50%, 1/3 experience a more moderate reduction
of seizure frequency, and in the remaining 1/3 there
is little or no effect of VNS4. This is also in accor-
dance with the results in the present study, although
the proportion of patients not responding to VNS was
somewhat higher in our study (43%). As opposed to
previous reports, three patients had an initial effect
that gradually diminished after 3–9 months.
The time interval from the implantation to a
seizure-reducing effect was achieved varied consid-
erably among the responders. Our experience is in
agreement with Uthman4 who concluded that patients
might be divided into three categories: those with a
rapid onset of effect (weeks), those with a gradual
onset of effect (months, even years), and those with
no effect at all. In four of our patients, the improved
seizure control was not only maintained but also in-
creased over time. This is also in agreement with
previous reports7, 11.
While VNS seems to reduce the occurrence and
severity of several seizure types, it was our clinical
impression that secondary generalized tonic–clonic
seizures responded more often than other seizure
types.
In open clinical trials, in patients with refractory
epilepsy, it is often difficult to avoid adjusting some
of the patients’ AEDs. In the present study, the med-
ication was altered in 19 patients (40%) compared to
the baseline period. However, only three of these pa-
tients were among the responders, and we believe that
these alterations only had marginal influence on their
seizure frequency. Nevertheless, it may be difficult to
interpret the results in such open trials: The observed
reduction in seizure frequency may be a result of a
true effect of chronic intermittent VNS, a synergistic
effect between VNS and the AEDs, a reflection of the
natural history of the epilepsy, or of a placebo effect.
The number of patients in this study, like in some
other studies12, 14, 15, is too small to evaluate efficacy
of VNS in patients with generalized epilepsy.
Most of the reported side effects in the present study
were mild and transient, but three patients demanded
explantation partly due to troublesome side effects.
Deaths have occurred during VNS treatment. In a
group of 791 patients with VNS followed for 2 years,
15 deaths were reported, of which six were consid-
ered to be SUDEP. The mortality rate was comparable
to those seen in studies of new AEDs in a population
with severe epilepsy. No increased mortality risk could
be attributed to VNS13. None of the three deaths that
occurred in this study had any apparent relation to the
VNS treatment. When 1/3 of the patients in the present
study reported a better quality of life, felt more alert,
were in a better mood, as a consequence of VNS, this is
in agreement with the results in another recent study16.
In a very difficult-to-treat epilepsy population VNS
offers a >50% reduction in seizure frequency in about
1/3, comparable to that of some of the new AEDs17,
but lower than for temporal lobectomy18. Compared
to AEDs, VNS may appear advantageous, as there
are no compliance problems, no risk of idiosyncratic
or central nervous side effects, and no need for regu-
lar blood monitoring. Moreover, the magnet may give
some patients a feeling that they are able to control
their seizure disorder. The patients may also turn off
the stimulation at any time. The treatment is reversible
as the NPC system, both the device and the electrodes,
can safely be removed19. This should be considered
in those patients in whom VNS has offered little or
no effect 2–3 years post implantation.
Before considering VNS, it is important to rule out
the possibility of epilepsy surgery. As the treatment
is invasive and associated with relatively high initial
costs, approximately US $10,000, it should, in our
opinion, only be offered those unable to tolerate or
benefit from AEDs, and those in whom a partial reduc-
tion of seizure frequency will significantly improve
their quality of life.
It is still a problem that VNS is not associated with
physiological markers which allow us to monitor
and adjust stimulation individually. In addition, there
are currently no patient- or epilepsy-related variables
that can be used prospectively to identify responders.
However, the latter problem may also be applied
to AEDs.
CONCLUSION
Although VNS appears to be an efficacious and safe
mode of treatment, it should, in our opinion, only
be offered to patients with medically and surgically
refractory seizures.
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